Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT.

J Urol. 2000 Jan;163(1):181-6.

PMID:
10604342
2.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
3.

Osteoporosis after orchiectomy for prostate cancer.

Daniell HW.

J Urol. 1997 Feb;157(2):439-44.

PMID:
8996327
4.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

5.

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.

Cancer. 2002 Nov 15;95(10):2136-44.

6.
7.

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Ross RW, Small EJ.

J Urol. 2002 May;167(5):1952-6. Review.

PMID:
11956415
8.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
9.

Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.

Israeli RS, Ryan CW, Jung LL.

J Urol. 2008 Feb;179(2):414-23. Review.

PMID:
18076933
10.

Bone health in men receiving androgen deprivation therapy for prostate cancer.

Eastham JA.

J Urol. 2007 Jan;177(1):17-24. Review.

PMID:
17161994
11.

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

J Urol. 2006 May;175(5):1679-83; discussion 1683.

PMID:
16600728
12.

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.

J Urol. 2006 Sep;176(3):972-8; discussion 978.

PMID:
16890673
13.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
14.

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.

Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.

Int J Urol. 2007 Dec;14(12):1071-5.

16.

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.

Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.

Urology. 2010 May;75(5):1131-7. doi: 10.1016/j.urology.2009.10.075. Epub 2010 Feb 16.

PMID:
20163839
17.

Management of treatment-related osteoporosis in men with prostate cancer.

Smith MR.

Cancer Treat Rev. 2003 Jun;29(3):211-8.

PMID:
12787715
18.
19.

Management of bone loss in men with prostate cancer.

Higano CS.

J Urol. 2003 Dec;170(6 Pt 2):S59-63; discussion S64. Review.

PMID:
14610412
20.

Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.

Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.

J Urol. 2007 Oct;178(4 Pt 1):1423-8. Epub 2007 Aug 16.

PMID:
17706711

Supplemental Content

Support Center